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Abstract 
Drug metabolism reactions are divided into two phases. Glucuronidation is an important 
phase II metabolism reaction that is catalyzed by UDP-glucuronosyltransferases (UGTs). 
Due to glucuronic acid conjugation, bioactive compounds become inactive, and lipophilic 
substances become more hydrophilic, which enhances their excretion to urine and bile. 
Aglycones can be endogenous or exogenous compounds, such as hormones and drugs. 
 
Synthetic glucuronide metabolites are needed as reference substances in drug research. 
Glucuronide conjugates have been synthesized by both chemical and enzymatic methods. 
The  aim  of  this  work  was  to  study  glucuronidation  of  aglycones  that  have  multiple  
glucuronidation sites. Glucuronide isomers of dobutamine, losartan, candesartan, and 
zolarsartan were synthesized by enzyme-assisted methods whereas clenbuterol 
glucuronides were synthesized chemically using the Koenigs-Knorr reaction. The 
structures and the glucuronidation sites of the synthesized compounds were determined by 
tandem mass spectrometry and nuclear magnetic resonance spectroscopy. From 
dobutamine, the glucuronide synthesis produced three O-glucuronide regioisomers. Both 
N- and O-glucuronides, including two acyl glucuronides, of losartan, candesartan, and 
zolarsartan were obtained. The Koenigs-Knorr reaction produced O-glucuronide 
stereoisomers of clenbuterol. The yields varied between 0.7 and 34.6% (0.5–6.8 mg). 
 
It is important to identify active UGT isoforms in order to understand drug-drug 
interactions, to clarify catalytic mechanisms, to assess the structure-function relationships, 
and to find isoform-selective probes. In this study, the glucuronidation activity of 
recombinant human UGTs was assessed using the synthesized glucuronides as reference 
compounds. In addition, species differences in glucuronidation were studied using liver 
microsomes from various animals. The formation of glucuronide isomers of dobutamine, 
losartan, candesartan, and zolarsartan brought a new perspective to evaluation of the 
structure-function relationships of UGTs and the results provided new data on their 
substrate specificities. UGT1A10 showed versatile substrate specificity whereas UGT1A3 
was highly selective towards N2 in the tetrazole ring. The glucuronidation activity of liver 
microsomes was different between species. Compared to animal liver microsomes, human 
liver microsomes glucuronidated the studied aglycones inefficiently. There were no 
distinct correlations between the glucuronidation properties of human liver microsomes 
and recombinant hepatic UGTs, so it is difficult to predict the glucuronidation in human 
liver microsomes from the data obtained with recombinant UGTs. 
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Abbreviations 
CYP cytochrome P450  
Da dalton 
DQFCOSY double quantum filtered correlated spectroscopy  
HMBC heteronuclear multiple bond correlation 
HPLC high performance liquid chromatography 
HSQC heteronuclear single quantum coherence 
Km Michaelis constant 
Ksi substrate inhibition constant 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser effect spectroscopy 
ROESY rotating Overhauser effect spectroscopy 
SN2 bimolecular nucleophilic substitution 
SPE solid-phase extraction 
UDP uridine 5’-diphosphate 
UDPGlcA UDP-glucuronic acid 
UGT UDP-glucuronosyltransferase 
UGT UGT gene 
UV ultraviolet 
Vmax maximal velocity 
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1 Introduction 
UDP-glucuronosyltransferases (UGTs, EC 2.4.1.17) are a family of enzymes that catalyze 
glucuronidation reactions. Glucuronidation is the major phase II metabolism reaction, 
where the substrate is conjugated to glucuronic acid. Both endogenous and exogenous 
compounds can serve as aglycones, and drugs are one important class of substrates of 
UGTs. 
 
This study deals with syntheses of glucuronides and UGTs. The glucuronidation 
activities of recombinant human UGTs and liver microsomes from various species 
towards selected drugs were screened. The studied drugs — dobutamine, losartan, 
candesartan, zolarsartan, and clenbuterol — can be metabolized to different glucuronide 
regioisomers or stereoisomers. To characterize the structures of the glucuronides, they 
were first synthesized in milligram scale and the glucuronidation sites were determined by 
two-dimensional nuclear magnetic resonance spectroscopy (NMR). 
 
Why is it important to identify the active UGT isoforms? Although glucuronidation is 
one of the most important phase II metabolism reactions, compared to cytochrome P450 
(CYP) catalyzed reactions that play central role in drug metabolism, its implication for 
drug therapy is still quite unclear. On the basis of enzyme activity assays it may be 
possible to understand UGT mediated drug-drug interactions. No crystal structure of any 
full-length UGT has been determined and the catalytic mechanisms are still under 
investigation. Therefore UGT screening assays can provide important information for 
evaluating the structure-function relationships of UGTs. The activities of individual UGTs 
are generally overlapping, which has caused a lack of isoform-selective probe drugs and 
inhibitors. Recombinant enzyme screening assays can reveal possible probe compounds or 
structures that could be modified to serve as selective probes. In the last decades it has 
been found that many UGTs are polymorphic and this highlights the importance of 
pinpointing the isoforms responsible for the glucuronidation of a given drug.  
1.1 Glucuronidation and UDP-glucuronosyltransferases 
Drug metabolism changes the chemical structure of lipophilic compounds so that they are 
more easily excreted from the body, usually by increasing the hydrophility of the molecule 
[1]. Simultaneously bioactive compounds are often inactivated. Metabolic reactions are 
classified into two phases. Oxidation, reduction, and hydrolysis — the main phase I 
reactions — are functionalization reactions: as consequence a functional group is added to 
the parent drug molecule. Phase II reactions form conjugates, since an acetyl, amino acid, 
sulphate, glucuronic acid, glutathione, or methyl group is conjugated to the drug or to the 
metabolite formed in the phase I reaction. The conjugation reactions are usually catalyzed 
by specific transferases. 
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Glucuronidation is considered to be the most important phase II metabolic reaction, 
and it is involved in the metabolism of large number of endobiotics and xenobiotics. The 
human UGTs that use UDP-glucuronic acid (UDPGlcA) as the co-substrate are classified 
into three subfamilies, UGT1A, UGT2A, and UGT2B, according to their amino acid 
sequence (Fig. 1) and gene structure [2]. The substrate specificities of individual UGTs are 
often very wide and partly overlapping, reducing the risk of drug interactions caused by 
metabolism via glucuronidation. Human UGT genes and their regulatory elements are 
polymorphic and this has become an important area of research, because of the possible 
risk of drug-induced adverse reactions [3-7]. Further knowledge of polymorphism can also 
help to predict susceptibility to cancer [3, 4]. 
 
 
 
Figure 1 Phylogenetic tree for UGTs. The homology of the enzymes at the amino acid level is 
presented [2, 3, 8]. 
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Metabolizing enzymes often appear in the tissues and organs that are prone to exposure 
to exogenic compounds, thus protecting the organism from foreign compounds. The liver 
is such an organ, as it is directly exposed to absorbed drugs and other xenobiotics from the 
intestine via the hepatic portal vein. The liver is the main organ where UGTs are 
expressed, although glucuronidation is also active in different parts of the gastrointestinal 
tract. UGTs are expressed in other extrahepatic tissues as well (Table 1). Polymorphic 
expression of UGTs produces inter-individual variation in the content of UGTs in tissues 
[9, 10]. 
Table 1. Expression of UGT isoforms in human tissues and organs. 
UGT isoform Tissues and organs Refs (and Refs. therein) 
1A1 Bile ducts, colon, liver, small intestine, 
stomach  
[6, 11-13] 
1A3 Bile ducts, colon, liver, small intestine, 
stomach 
[6, 11-13] 
1A4 Bile ducts, colon, liver, small intestine [6, 11-13] 
1A5 Colon, liver, small intestine, stomach [14] 
1A6 Bile ducts, brain, colon, liver, small intestine, 
stomach 
[6, 11-13] 
1A7 Esophagus, lung, small intestine, stomach [6, 11-13] 
1A8 Colon, esophagus, kidney, small intestine [6, 11-13] 
1A9 Colon, esophagus, kidney, liver [6, 11-13] 
1A10 Bile ducts, colon, esophagus, kidney, small 
intestine, stomach 
[6, 11-13] 
2A1 Brain, fetal lung, olfactory epithelium [6, 11] 
2A2 Liver, small intestine [8] 
2A3 Adipose, colon, kidney, liver, pancreas, small 
intestine, stomach, testis 
[15] 
2B4 Liver, small intestine [6, 11-13] 
2B7 Brain, colon, esophagus, kidney, liver, 
pancreas, small intestine 
[6, 11-13] 
2B10 Esophagus, liver, mammary gland, prostate, 
small intestine 
[6, 11-13] 
2B11 Adipose, adrenal, kidney, liver, lung, mammary 
gland, prostate, skin 
[6, 11-13] 
2B15 Esophagus, liver, prostate, small intestine [6, 11-13] 
2B17 Liver, prostate [6, 11, 12] 
2B28 Liver, mammary gland [6] 
 
UGTs are transmembrane proteins located in the endoplasmic reticulum [13, 16-18]. 
About 95% of the polypeptide chain is located on the lumenal side, including the catalytic 
domain. The access of hydrophilic UDPGlcA from the cytosol into the endoplasmic 
reticulum lumen across the membrane is restricted. Therefore, in in vitro studies, the 
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glucuronidation activity can be increased with membrane-disrupting agents like 
phospholipase, detergents, sonication, and alamethicin, probably due to the greater access 
of UDPGlcA (and aglycone) to the enzyme active site [16, 17, 19]. It has been proposed 
that there are transporters to carry the co-substrate into the lumen of the endoplasmic 
reticulum, as well transporters to carry the glucuronide formed out to the cytosol [13, 17, 
18]. Even the action of UGTs as transporters has been suggested [13, 17, 18]. In particular 
it has been speculated that two UGT monomers could form a dimer, which would then act 
as a channel carrying the UDPGlcA to the active site. Indeed, it strongly appears that 
UGTs act as dimers or oligomers, where two or more UGT polypeptide chains form 
homo- or heteromers [13, 17, 18, 20]. 
 
UGTs catalyze the conjugation of UDPGlcA to a nucleophilic functional group of the 
substrate that already exists in the aglycone or is formed in a phase I metabolic reaction 
(Fig. 2). Aryl, alkyl, enolic, and acyl hydroxy groups are glucuronidated to O-
glucuronides (ether or ester linkage) whereas N-glucuronides are formed from amines and 
sulfonamides [16, 17]. S- and C-glucuronides, formed from thiols and enol ?-carbon 
atoms, are rare. The enzymatic glucuronidation reaction is believed to be a bimolecular 
nucleophilic substitution (SN2) reaction where the aglycone substrate attacks the 
UDPGlcA and an inversion of the configuration converts the glucuronic acid from ?- to 
the ?-anomer. 
 
Figure 2 Glucuronidation of compound RX-H. The UGT-catalyzed reaction produces ?-D-
glucuronides from ?-anomeric UDPGlcA and aglycone substrate. The X refers to O, 
N, or S atoms. 
Glucuronidation is considered as a detoxification reaction: the compound usually loses 
its biological activity, although some exceptions exist. Probably the most well-known 
active glucuronide is morphine 6-O-glucuronide, which has even more analgesic action 
than morphine [21, 22]. Another example is ?-hydroxymidazolam glucuronide which is 
active and may accumulate in patients with renal failure, causing prolonged sedation [23]. 
N-O-Glucuronides of hydroxamic acids, formed from the glucuronidation of an N-hydroxy 
group, are also considered reactive metabolites [21]. They can react with nucleophiles in 
cell, such as methionine, tryptophan, and guanosine residues in proteins and DNA. 
However, the formation of N-O-glucuronides is rare, and their reactivity has not been 
widely tested. 
 
The most noteworthy group of reactive glucuronide metabolites is acyl glucuronides 
(1) (Fig. 3), which are formed from carboxylic acids. Electrophilicity of the ester group 
carbonyl carbon leads to instability of the acyl glucuronide [21, 24-27]. Susceptibility to 
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hydrolysis, which is more rapid at neutral and basic pH than with acidic conditions and 
can  even  be  catalyzed  by  esterases  and  ?-glucuronidase,  can  prolong  the  half-life  of  
carboxylic-acid containing drugs due to enterohepatic recirculation. In addition, an 
intramolecular rearrangement called acyl migration can take place, and either the acyl 
glucuronide itself or the migration isomers may bind covalently to macromolecules, such 
as proteins or DNA, causing adverse effects. Acyl glucuronides can form protein adducts 
by two distinct types of reactions. In the transacylation reaction, glucuronic acid (2) is lost 
and aglycone is directly bound to the protein (3) (Fig. 3). The other reaction type is called 
glycation, where the 2-O-, 3-O-, or 4-O-acyl migration product (4, 5, or 6) undergoes 
transient ring opening to give an open-chain aldehyde (7)  that  reacts  further  with  amino  
groups of biomolecules and forms an imine (Schiff base) (8).  Amadori  rearrangement of 
the imine (8)  to  ketone  (9)  is  possible  in  the  cases  of  3-O- and 4-O-acyl migration 
products. The migration isomer can undergo anomerzation by a ring closing reaction of 
the open-chain aldehyde (7) leading to an ?-configuration of the isomer (10). Overall, the 
reactivities  of  acyl  glucuronides  differ  enormously  and  depend  on  the  electronic,  steric,  
and  other  characteristics  of  the  drug  aglycone  [26].  For  example,  diclofenac  is  a  
carboxylic acid-containing nonsteroidal anti-inflammatory agent, the therapeutic use of 
which leads sometimes to rare hepatotoxicity [28]. The toxicity is caused by reactive 
metabolites. Diclofenac is glucuronidated by UGT2B7 and the acyl glucuronide formed 
can bind covalently to proteins. However, diclofenac can also be bioactivated by 
oxidation. The biochemical mechanism of diclofenac hepatotoxicity is not fully 
understood, but acyl glucuronidation certainly plays a role. 
 
Figure 3 Reactivity of acyl glucuronide (1) [21, 24-27]. The figure shows glycation of a 3-O-
isomer (5), but similar reactions take place with other isomers (4 and 6). (See text for 
details.) 
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1.2 Glucuronides as Standard Compounds 
Drug metabolites, including glucuronides, are needed as reference substances for 
analytical studies in pharmacological, toxicological, and biopharmaceutical research. 
However, only a few synthetic glucuronide metabolites are commercially available. Small 
amounts of glucuronide conjugates can be isolated from urine or tissues after 
administration  of  the  drug  aglycone  to  humans  or  laboratory  animals.  However,  this  
method is very laborious given the small amount of purified compound obtained. In 
addition, the ethical issues are noteworthy, and these cannot be simply addressed by using 
laboratory animals since they do not necessarily produce similar metabolites as humans 
do. 
 
The Koenigs-Knorr reaction is the most widely applied method to chemically 
synthesize alkyl and aryl O-glucuronide metabolites [29, 30]. In this reaction the aglycone 
is coupled with methyl acetobromo-?-D-glucuronate (11) (Fig. 4) in the presence of silver 
salts.  The  first  step  of  the  synthesis  yields  fully  protected  ?-D-glucuronide (12), and the 
protecting groups are then hydrolyzed with alkali. In addition to the desired ?-D-
glucuronide (13), the reaction often yields the ?-anomer (14) and ortho ester (15) as by-
products. If the aglycone has multiple glucuronidation sites, chemical synthesis can yield a 
mixture of mono- and polyglucuronides unless the unwanted glucuronidation sites are 
protected. The reaction gives glucuronides in variable yields depending on the catalyst, 
solvent, aglycone, and the ratio of the starting materials used. Other methods have been 
used for the synthesis of glucuronides too; the main differences between the reactions are 
in the glycosyl donor [27, 29, 30]. N-Glucuronides can be synthesized by the reaction of 
glucuronic acid and amine. Modifications of the Koenigs-Knorr reaction have also been 
used for production of N-glucurondies. 
 
Figure 4 Koenigs-Knorr reaction [29, 30]. Methyl acetobromo-?-D-glucuronate (11) is 
conjugated to aglycone (ROH) yielding protected ?-D-glucuronide (12) and, as by-
product, ?-anomer (14) and ortho ester (15). The protecting groups are hydrolyzed 
with alkali to produce the ?-D-glucuronide (13). 
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Glucuronides can be synthesized with the help of enzymes. Different kinds of enzyme 
preparations have been used, such as perfused rat liver [31], liver microsomes from human 
[32-35], bovine [36, 37], dog [32], pig [36], and Aroclor 1254-induced rat [38-40], and 
even recombinant human UGTs [41]. Enzyme-assisted syntheses have mostly been 
utilized to produce O-glucuronides, but syntheses of N-glucuronides have also been 
described [35, 41]. Enzymes produce mainly monoglucuronides, even regio- or 
stereoselectively. In addition, the advantage of UGT-catalyzed synthesis of glucuronides is 
the formation ?-anomers only. Immobilization of microsomes has been used to enable 
easy  separation  of  products  from  proteins  after  the  synthesis  reaction  [42-45].  Also,  the  
stability of enzymes is often improved by immobilization, leading to the possibility of 
increasing the incubation time or even reusing the proteins. Compared to free microsomes, 
better enzyme activities have sometimes been obtained with immobilized microsomes.  
 
Production of glucuronides for reference material without isolation and purification 
can sometimes be appropriate, for example in qualitative chromatographic analyses that 
include the separation of the conjugate and unreacted aglycone. Then mass spectrometry 
(MS) or NMR spectroscopy instruments could be coupled to chromatography, thus 
allowing a method to identify and characterize the substances. Even immobilized enzyme 
reactors have been developed that synthesize, separate, and detect the metabolites on-line 
[46-48]. 
Structural Characterization of Glucuronides 
Nowadays, mass spectrometry is probably the most often used method to identify 
glucuronides. The advantage of the MS technique is that only a very small quantity of 
compound is required to obtain accurate tandem mass (MS/MS) spectra. Using positive 
ion MS/MS, the typical fragmentation is the neutral loss of the glucuronide moiety (176 
Da), and the product ions include the aglycone and the fragments of the aglycone. In 
negative ion mode, characteristic fragment ions are observed from the glucuronide moiety 
at m/z 175 [C6H7O6]- and m/z 113 [C6H7O6 – CO2 – H2O]-. Thus, the determination of the 
conjugation site is not generally possible and the glucuronide isomers often have similar 
MS/MS spectra. However, some exceptions exist in the literature. Conjugation at an 
aliphatic hydroxyl group can be seen in negative ion mode as a product ion at m/z 193, 
which is a deprotonated glucuronic acid [C6H9O7]-. This kind of cleavage is not possible 
for glucuronides conjugated at an aromatic hydroxyl, nor for N-glucuronides [33, 37, 49]. 
Derivatization of glucuronides before MS/MS analysis has also been exploited for 
determination of the conjugation sites [50, 51].  
 
NMR is required for detailed structural characterization of glucuronides. The site of 
glucuronidation can be identified by comparing the chemical shifts of the glucuronide to 
those of the aglycone. The largest changes in chemical shifts upon glucuronidation are 
found in the atoms located near the conjugation site. Nevertheless, if the aglycone has 
multiple functional groups at which the glucuronide can be conjugated, and especially if 
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the functional groups are close to each other in the molecule, it can be difficult to 
determine the glucuronidation site with confidence. Nuclear Overhauser effect (NOE), 
rotating Overhauser effect (ROESY), and heteronuclear multiple bond correlation 
(HMBC) spectroscopy are all useful NMR techniques for verifying the structures and 
particularly the site of glucuronidation. In addition, the anomeric configuration can easily 
be determined by NMR. Enzyme-catalyzed reactions produce only glucuronides having a 
?-configuration, but chemical syntheses can yield both ?- and ?-anomers. Vicinal 
couplings between two axial protons, GH1 and GH2, in a glucuronide ring are 8-9 Hz, 
indicating the ?-anomeric configuration, whereas in other cases the coupling would be less 
than 4 Hz [52-54]. The disadvantage of 13C and two-dimensional NMR studies is that a 
sufficient amount of compound, in the milligram range, is required. 
1.3 Studying Glucuronidation In Vitro 
In the drug discovery process, metabolism studies of a drug candidate begin with 
preclinical trials. The aim is to detect poor drug candidates as early as possible in order to 
avoid unnecessary clinical trials that consume time and money. The preclinical 
metabolism studies are carried out both in vivo with animals and in vitro, and the purpose 
is to predict human pharmacokinetics and drug-drug interaction risks. It is important to 
expose laboratory animals to the same metabolites as the drug consuming humans would 
be exposed. However, species differences are large, and it is difficult to predict and 
extrapolate how the drug would be metabolized in humans. Therefore, knowledge of the 
characteristics of drug metabolism in laboratory animals is needed.  
 
In vitro metabolism studies can be carried out with different kinds of preparations such 
as perfused organs, tissue slices, isolated cells, subcellular organelles, and purified 
enzymes. Microsomes are the most commonly-used source of enzymes for oxygenation 
and glucuronidation research, because the use of this model is simple [55]. Most often the 
microsomes are derived from liver, but also extrahepatic organs are used. To obtain 
microsomes, the tissue is homogenized and then fractionated by differential centrifugation. 
Nuclei, mitochondria, and other denser materials are removed at a lower centrifugation 
force (10 000 g) and soluble enzymes stay in the supernatant, even at a higher 
centrifugation force (100 000 g). The microsomal fraction is the pellet obtained at the 
higher centrifugation force. The microsomes contain mainly membranes of endoplasmic 
reticulum and the enzymes bound to them. Although the intracellular architecture is lost, 
microsomes have the advantage that different enzyme isoforms are represented with their 
natural variability. Genetic and environmental variations are present but they can be 
minimized by pooling samples from several individual donors [56]. In addition, the 
presence of native UGT oligomers, which can affect the enzyme activities, is likely 
possible in microsomes. Compared to microsomes, whole cell systems have the advantage 
that  they  also  contain  soluble  enzymes  and  transporter  proteins  [55,  57].  Studies  on  the  
coupling of conjugation enzymes and efflux transporters have currently generated a lot of 
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interest, since their interplay has a significant impact on the bioavailability, detoxification, 
and interactions of drugs [58]. 
 
The inter-individual differences in drug metabolism, and thus in drug action, can be 
caused by genetic, physiological, pathological, and environmental factors. For example 
enzyme polymorphism, intestinal and liver diseases, and alcohol abuse can have an effect 
on the metabolism of a drug. If the enzymes that metabolize a drug are identified, the 
inter-individual differences can be understood and in some cases even predicted. Enzyme 
selective antibodies, inhibitors, and probes have been used to identify metabolic enzymes, 
but unfortunately not many of these are available for UGTs yet. Nowadays the availability 
of recombinant enzymes has increased their use in metabolism research. In addition to 
avoiding difficult extrapolation to human metabolism from animal metabolism data, 
ethical considerations support the development of methods to study drug metabolism in 
vitro with recombinant human enzymes [59, 60]. Recombinant human UGTs have been 
expressed in mammalian and insect cells [61]. They provide a tool to study substrate 
specificity, and those findings can be used to evaluate tissue specific glucuronidation and 
to analyze structure-function relationships of UGTs. Catalytic amino acids within the 
substrate binding site can be identified with the help of recombinant UGT mutants. 
Recently, clarifying the effects of polymorphic UGTs on drug treatment has become a 
significant application of recombinant UGTs. However, it is still uncertain if the results 
from recombinant enzymes can be extrapolated to microsomes, still less to the in vivo 
situation [57]. 
Dobutamine, Losartan, Candesartan, Zolarsartan, and Clenbuterol as 
Subjects of Glucuronidation Research 
Based on the published reports, dobutamine [62-64], losartan [65-67], candesartan [51, 
68], zolarsartan (GR117289, also called zolasartan) [69], and clenbuterol [70, 71] (Fig. 5) 
are metabolized via conjugation to glucuronic acid without a phase I metabolism reaction. 
All these compounds contain several possible glucuronidation sites. The likely formation 
of glucuronide isomers makes the research on these aglycones interesting. 
 
Dobutamine is a synthetic derivative of the endogenous catecholamine dopamine (Fig. 
5). It moderately stimulates ?1-  and  ?2-adrenergic receptors and strongly stimulates ?1- 
adrenergic receptors, thus causing an inotropic effect on the heart. It is used for the 
treatment of cardiac failure. Dobutamine is administered as a continuous infusion since its 
half-life in plasma is only 2 minutes [72]. Depending on the animal species, the 
metabolites of dobutamine include 3-O-methyldobutamine as well as glucuronide and 
sulfate conjugates of dobutamine and 3-O-methyldobutamine [62-64]. Studies with 
recombinant UGTs showed that rat 2B1 and human 1A6 and 1A9 glucuronidated 
dobutamine, but rat 1A6 and human 1A1, 2B7, and 2B15 did not [73, 74]. More than one 
dobutamine glucuronide has been separated by chromatography and detected [64, 73] 
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indicating  the  formation  of  isomers.  However,  their  structures,  especially  the  
glucuronidation sites, have not been determined. 
 
The renin-angiotensin system is an important drug target for the treatment of high 
blood pressure. The hypertensive effect of angiotensin II can be prevented by inhibiting 
the angiotensin-converting enzyme that catalyzes its formation. Another strategy is to 
block the binding of angiotensin II to AT1-receptors. AT1 antagonists are called “sartans”, 
and losartan was the first sartan on market. Candesartan and zolarsartan are structural 
analogues of losartan: they all have a tetrazole ring and there is a carboxyl group in 
candesartan and zolarsartan (Fig. 5). Losartan is partly metabolized to an active carboxylic 
acid derivative. Two different glucuronide metabolites are formed by biotransformation: 
tetrazole-N2-glucuronide by monkeys, rats, dogs, and humans, and O-glucuronide by 
monkeys and rats [65-67, 75]. In addition, losartan N1-glucuronide has been synthesized 
chemically [65]. Candesartan is administered as a prodrug, candesartan cilexetil, that is 
hydrolyzed during the absorption process. This improves its oral bioavailability. Most 
candesartan is excreted unchanged [76], but it has been found that rats and dogs produce 
two candesartan glucuronide metabolites, the tetrazole-N2-glucuronide and the O-
glucuronide (acyl glucuronide) [51, 68]. Zolarsartan is not in clinical use, but it is also an 
active AT1 antagonist, both in vitro [77] and in vivo [78]. Glucuronic acid conjugates of 
zolarsartan have been found in rat and dog bile [69]. Dogs produced both the tetrazole-N2-
glucuronide and the O-glucuronide (acyl glucuronide) whereas rats produced only the O-
glucuronide (acyl glucuronide) of zolarsartan.  
 
The sympathomimetic clenbuterol (Fig. 5) selectively stimulates ?2-receptors, 
therefore it is a bronchodilator. It is used for treatment of asthma and chronic obstructive 
pulmonary disease in both human and veterinary medicine. Athletes have abused 
clenbuterol  because  of  its  possible  anabolic  effect  and  reduction  of  body fat.  It  has  also  
been used illegally in cattle, which has even caused toxic effects to humans consuming 
liver or meat that contained residues of clenbuterol [79-81]. A part of the clenbuterol dose 
is excreted as the parent compound, and the amount of unchanged drug depends on the 
species [70, 82]. The main metabolites include 4-amino-3,5-dichloromandelic acid, 4-
amino-3,5-dichlorohippuric acid, and clenbuterol hydroxylamine [70, 82-88]. In addition, 
N- and O-glucuronides have been reported as metabolites of clenbuterol [70, 71]. 
 
The site-specific glucuronidation of one aglycone by individual recombinant human 
UGTs provides new insights into substrate specificity of human UGTs. The knowledge of 
interspecies differences in glucuronidation activity in liver microsomes can be utilized in 
toxicology  tests  and,  in  addition,  the  suitability  of  microsomes  as  catalysts  in  enzymatic  
synthesis of metabolites can be assessed. Synthetic glucuronides are needed as reference 
material  for  these  kinds  of  assays,  but  at  present  only  a  few  glucuronide  conjugates  are  
commercially available. 
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Figure 5 Structures of the studied compounds. The sartans, losartan, candesartan, and 
zolarsartan, are structural analogues. 
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2 Aims of the Study 
The primary aim of the study was to investigate the ability of human recombinant UGTs 
and liver microsomes from different animals to catalyze glucuronide isomers. For this 
purpose suitable aglycones were selected and their glucuronide isomers were synthesized 
and characterized.  
 
The detailed aims of the research were 
 
- to synthesize glucuronide regioisomers of dobutamine (I), losartan (II), candesartan 
(II), and zolarsartan (II) using enzyme-catalyzed reactions and to characterize the 
structures of the synthesis products 
 
- to synthesize glucuronide isomers of clenbuterol (IV) using the Koenigs-Knorr 
reaction and characterize the structures of the synthesis products 
 
- to screen the activity of recombinant human UGTs and liver microsomes from various 
species in the production of different glucuronide isomers of dobutamine (I), losartan 
(III), candesartan (III), zolarsartan (III), and clenbuterol (IV) 
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3 Materials and Methods 
The materials and methods used in this study are summarized in this section. More 
detailed descriptions can be found in the original publications (I–IV). 
3.1 Chemicals and Enzyme Preparations 
Chemicals and enzyme preparations used in the study are listed in Tables 2 and 3, 
respectively. All the other reagents and solvents were of high performance liquid 
chromatography (HPLC) or analytical grade. 
Table 2. Chemicals used in the study. 
Chemical Producer Publication 
Dobutamine 
(hydrochloride salt) 
Eli Lilly & Co, Indianapolis, IN, USA I 
Candesartan AstraZeneca, Mölndal, Sweden II, III 
Clenbuterol 
(hydrochloride salt) 
Sigma-Aldrich St. Louis, MO, USA IV 
Losartan (potassium salt) Merck, Rahway, NJ, USA II, III 
Methyl acetobromo-?-D-
glucuronate 
Sigma-Aldrich St. Louis, MO, USA IV 
Saccharic acid 1,4-lactone Sigma-Aldrich, St. Louis, MO, USA I, II, III, IV 
Silver carbonate Sigma-Aldrich, St. Louis, MO, USA IV 
Uridine-5’-
diphosphoglucuronic acid 
(trisodium salt) 
Sigma-Aldrich, St. Louis, MO, USA I, II, III, IV 
Zolarsartan GlaxoSmithKline, Hertfordshire, UK II, III 
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Table 3. Enzyme preparations used in the study. 
Enzyme preparation Producer Publication 
Aroclor 1254-induced 
male Sprague-Dawley rat 
liver microsomes 
Faculty of Pharmacy, Division of 
Pharmaceutical Chemistry, University 
of Helsinkia 
I, II, III, IV 
Bovine liver microsomes Faculty of Pharmacy, Division of 
Pharmaceutical Chemistry, University 
of Helsinkia 
III, IV 
Dog liver microsomes Orion Corporation, Espoo, Finlandb IV 
Human UGTs 1A1, 1A3–
1A10, 2B4, 2B7, 2B10, 
2B15, 2B17, and 2B28 
Faculty of Pharmacy, Division of 
Pharmaceutical Chemistry, University 
of Helsinkic 
I (not 1A5, 2B10, 
2B17, 2B28), II 
(only 1A3, 1A8, 
1A10), III, IV 
Male New Zealand white 
rabbit liver microsomes 
In Vitro Technologies, Baltimore, MD, 
USA 
I, III, IV 
Moose liver microsomes Faculty of Pharmacy, Division of 
Pharmaceutical Chemistry, University 
of Helsinkia 
II, III, IV 
Pig liver microsomes Faculty of Pharmacy, Division of 
Pharmaceutical Chemistry, University 
of Helsinkia 
I, II, III, IV 
Pooled human liver 
microsomes 
BD Gentest, Woburn, MA, USA I, III, IV 
aPrepared as described in Ref. [89]. 
bPrepared as described in Ref. [90]. 
cPrepared as described in Refs. [91-93]. 
3.2 Glucuronide Syntheses (I, II, IV) 
Glucuronides were synthesized by enzymatic (I, II) and traditional chemical (IV) methods.  
Enzyme-Assisted Syntheses of Glucuronides (I, II) 
Three dobutamine glucuronide regioisomers were synthesized in one reaction mixture 
using pig liver microsomes as catalyst (I). Regioisomers of losartan, candesartan, and 
zolarsartan glucuronides were synthesized in separate reactions using liver microsomes 
from different animals or recombinant human UGTs as catalysts (II). All reaction mixtures 
contained 5 mM saccharic acid 1,4-lactone, 5 mM UDPGlcA, 5 mM MgCl2, and 50 mM 
phosphate buffer (pH 7.4). The protein concentration of the enzyme catalyst was 1–2.5 
mg/ml in the reaction mixture. The aglycone concentrations varied between 0.2 and 1.5 
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mM, and in reactions for dobutamine glucuronides, losartan N1-glucuronide, and 
zolarsartan N2-glucuronide, aglycone was added in two portions, at the beginning and in 
the middle of the incubation time. Reactions were incubated at 37 °C under continuous 
stirring for 5–48 hours. Proteins were removed from the reaction mixtures either by 
precipitation and centrifugation or directly by centrifugation (26,700 g, 10 min, 6 °C), and 
the supernatants were solid-phase extracted (SPE). SPE elution solvents were evaporated 
and the crude products were dissolved in the HPLC eluent that was used in fractionation. 
The glucuronides were fractionated using an Agilent 1100 HPLC equipped with an 
autosampler,  a  UV  multiple  wavelength  detector,  and  a  fraction  collector  (Agilent  
Technologies, Waldbronn, Germany). The collected glucuronide fractions were 
evaporated, and salts were removed from dobutamine, losartan, and candesartan 
glucuronides by SPE. Finally all glucuronides were lyophilized. 
Chemical Synthesis of Glucuronides (IV) 
Clenbuterol glucuronide diastereomers were synthesized by the Koenigs-Knorr reaction 
(Fig. 6). An alkaline aqueous solution of clenbuterol hydrochloride was extracted with 
diethyl ether to obtain the free base of clenbuterol. The ether was evaporated and the 
residue was dissolved in toluene. Methyl acetobromo-?-D-glucuronate and Ag2CO3 were 
added to the solution. After stirring at 75 °C for 25 hours, the reaction mixture was 
allowed to cool to room temperature. The mixture was filtered and the filtrate was 
evaporated to give a yellow residue. The residue was dissolved in methanol, and an 
equivalent volume of 1 M LiOH aqueous solution was added. The reaction mixture was 
stirred at room temperature for 28 hours, and finally the solvents were evaporated in 
vacuum and the crude products were dissolved in the eluent that was used in fractionation. 
The clenbuterol glucuronides were fractionated by a Waters preparative liquid 
chromatograph (Waters Corporation, Milford, MA, USA) equipped with a binary gradient 
pump, an autosampler, an active flow splitter, an HPLC pump, a UV diode array detector, 
an ion spray source, a MS detector (Waters micromass ZQ), and a fraction collector. Two 
clenbuterol glucuronide fractions were collected, evaporated, and lyophilized. 
Purities of Synthesis Products  
Purities of the synthesis products were assessed using an Agilent 1100 Series HPLC 
equipped with an autosampler and Agilent 1100 Series fluorescence or UV diode array 
detectors (Waldbronn, Germany). The amounts of impurities were calculated using the 
fluorescence exicitation and emission wavelengths of 285 nm and 313 nm for dobutamine 
glucuronides (I) and UV wavelengths of 256 nm, 210 nm, 306 nm, and 254 nm for 
losartan, candesartan, zolarsartan, and clenbuterol glucuronides (II, IV), respectively. 
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Figure 6 Synthesis of clenbuterol glucuronides from racemic clenbuterol by the Koenigs-Knorr 
reaction. 
Structural Characterization 
The mass spectrometric structure characterizations of isolated glucuronides were carried 
out on the instruments given in Table 4. The dobutamine glucuronides (I) were measured 
by  direct  infusion,  whereas  HPLC  with  a  short  analysis  time  was  used  for  other  
glucuronides (II, IV) before MS analyses. The experiments were performed both in 
positive and negative ion modes. 
Table 4. MS instrumentation used in the study. 
Mass spectrometer Producer Compounds Publication 
API 3000 triple 
quadrupole 
MDS Sciex, Toronto, 
Ont, Canada 
Dobutamine glucuronides, 
Losartan O-glucuronide, 
Losartan N2-glucuronide, 
Candesartan glucuronides, 
Clenbuterol glucuronides 
I, II, IV 
Quadrupole time-of-
flight 
Q-TOF Micro 
Waters/Micromass, 
Manchester, UK 
Losartan N1-glucuronide, 
Zolarsartan glucuronides 
II 
 
The NMR characterizations of isolated glucuronides were carried out on the 
instruments given in Table 5. For comparison, NMR spectra were recorded for aglycones 
as well. Interglycosidic correlations for determination of glucuronidation sites were 
observed from NOE, ROESY, and/or HMBC spectra (Table 6). 
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Table 5. NMR instrumentation used in the study. 
NMR spectrometer Producer Note Publication 
Varian 300 MHz 
mercury plus 
Varian, Inc., Palo 
Alto, CA, USA 
 II, IV 
Varian Unity 500 
MHz 
Varian, Inc., Palo 
Alto, CA, USA 
gHX nano-NMR probe for the 
heteronuclear experiments 
I 
Varian Unity Inova 
600 MHz 
Varian, Inc., Palo 
Alto, CA, USA 
cold probe II, IV 
Table 6. NMR experiments for structure characterization of synthesized glucuronides. a 
Glucuronide Experiment Publication 
Phenolic dobutamine O-glucuronide 1D 1H, 1D 13C, DQFCOSY, 
NOESY, HSQC, HMBC 
I 
Catecholic dobutamine para O-glucuronide 1D 1H, DQFCOSY, NOESY, 
HSQC, HMBC 
I 
Catecholic dobutamine meta O-glucuronide 1D 1H, 1D 13C, DQFCOSY, 
NOESY, HSQC, HMBC 
I 
Losartan glucuronides 1D 1H II 
Candesartan glucuronides 1D 1H, NOESY, HMBC II 
Zolarsartan O-glucuronide 1D 1H II 
Zolarsartan N-glucuronides 1D 1H, ROESY II 
Clenbuterol O-glucuronides 1D 1H, HSQC, HMBC IV 
aDQFCOSY, double quantum filtered correlated spectroscopy; NOESY, nuclear Overhauser effect 
spectroscopy; HSQC, heteronuclear single quantum coherence; HMBC, heteronuclear multiple bond 
correlation; ROESY, rotating Overhauser effect spectroscopy. 
3.3 Enzyme Activity Assays (I, III, IV) 
Glucuronidation screening assays of dobutamine (I), losartan (III), candesartan (III), 
zolarsartan (III), and clenbuterol (IV) with recombinant human UGTs and liver 
microsomes from various species were carried out in 250 µl reactions containing various 
concentrations of aglycone, 5 mM saccharic acid 1,4-lactone, 5 mM UDPGlcA, 5 mM 
MgCl2, 50 mM phosphate buffer (pH 7.4), and 625 µg protein (recombinant UGT 
membrane or microsome). The substrates were added as dimethylsulfoxide solution (2% 
in the final reaction volume). Enzyme reactions were incubated at 37 °C for four hours. 
 
Kinetic analyses of the formation of losartan N2-glucuronide were carried out with 
human liver microsomes and recombinant UGTs 1A1, 1A3, and 2B7 (III). Concentration 
of losartan in the samples varied between 2 and 600 µM. The protein concentration and 
incubation time were within the linear range with respect to both parameters. Otherwise 
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the reactions were carried similarly to the screening assays described above. The kinetic 
parameters were obtained by fitting the observed velocities to kinetic models using 
GraphPad Prism 4.02 for Windows (GraphPad Software Inc., San Diego, CA, USA). The 
kinetic models were Michaelis–Menten (v = Vmax [S]  /  (Km +  [S]))  and  the  substrate  
inhibition equation (v = Vmax / (1 + (Km / [S]) + ([S] / Ksi))). 
 
The enzyme reactions were analyzed by an Agilent 1100 Series HPLC equipped with 
an autosampler and the Agilent 1100 Series fluorescence or UV multiwavelength detector 
(Waldbronn, Germany). 
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4 Results and Discussion 
The results obtained in this work are described and discussed briefly in this section. More 
details can be found in the original publications (I-IV). 
4.1 Glucuronide Syntheses 
Altogether, 13 different glucuronides were synthesized from dobutamine, losartan, 
candesartan, zolarsartan, and clenbuterol. Clenbuterol glucuronides were synthesized by 
the Koenigs-Knorr reaction (IV), whereas the others were prepared using enzyme-assisted 
synthesis (I, II). 
Yields and Purities 
The yields and purities of the synthesized glucuronides are presented in Table 7. The 
amounts of glucuronides obtained in this study were sufficient for two-dimensional NMR 
analyses to characterize the detailed structures of the synthesis products. The synthesized 
glucuronides were also used as reference compounds in enzyme screening assays (I, III, 
IV). Over 90% purity was observed for nine glucuronides and those could also be used as 
standards in quantitative analytical studies. The synthesized losartan N2-glucuronide was 
used as a standard compound for enzyme kinetic analyses (III). In this study the purities 
were assessed using HPLC with fluorescence (I)  or UV (II,  IV) detection, assuming that 
the impurities have the same fluorescence or absorbance as the glucuronide isomer. 
Impurities that did not have a chromophore were not detected. For more exact results of 
the purities, evidence obtained with other methods could have been included. Residues of 
the aglycone and other isomers were identified on the basis of their retention times, but the 
origin of the other impurities found were not studied in detail. It is obvious that some of 
the detected impurities were formed by degradation after isolation of the glucuronides, 
since the purity analyses were performed by liquid chromatography with a C18 reversed 
phase column, as was the separation done when isolating the glucuronides by 
fractionation. Contamination of the synthesis products is also possible. 
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Table 7. The yields and purities of synthesized glucuronides. 
Glucuronide (Publication) Enzyme source / methoda Yield Purityb 
Dobutamine (I)c    
Phenolic O-glucuronide 1.7 mg (4.6%) > 97% 
Catecholic para O-glucuronide 3.5 mg (9.3%) > 97% 
Catecholic meta O-glucuronide 
Pig liver microsomes 
6.2 mg (16.6%) > 97% 
    
Losartan (II)    
O-Glucuronide Bovine liver microsomes 0.5 mg (1.1%) > 97% 
N1-Glucuronide UGT1A10 0.9 mg (2.2%) > 97% 
N2-Glucuronide Moose liver microsomes 2.0 mg (7.4%) > 97% 
    
Candesartan (II)    
Acyl O-glucuronide UGT1A8 0.9 mg (2.8%) > 85% 
N2-Glucuronide UGT1A3 1.5 mg (4.0%) > 90% 
    
Zolarsartan (II)    
Acyl O-glucuronide Pig liver microsomes 1.6 mg (4.3%) > 60% 
N1-Glucuronide Rat liver microsomes 3.6 mg (34.6%) > 80% 
N2-Glucuronide UGT1A3 6.8 mg (33.9%) > 97% 
    
Clenbuterol (IV)c    
O-Glucuronide 1 1.6 mg (0.9%) > 90% 
O-Glucuronide 2 
Koenigs-Knorr 
1.3 mg (0.7%) > 75% 
aClenbuterol glucuronides were synthesized by the Koenigs-Knorr reaction, whereas the others were 
prepared using enzyme-assisted synthesis. 
bDetermined by HPLC-UV, except dobutamine glucuronides, which were determined by HPLC-
fluorescence. 
cAll glucuronide isomers from the aglycone were synthesized in one reaction mixture. 
 
In this study, the percentage yields of the glucuronides were often low (Table 7). Large 
variation in yields of glucuronide syntheses have been described: 4–78% for enzyme-
assisted syntheses [35, 36, 38-40] and 0.6–82% for Koenigs-Knorr reaction [30]. 
Compared to these results the yields obtained in this study were not as high as could have 
been expected. Higher yields could have been obtained by further optimization of the 
reactions. The preliminary experiments for the enzyme-assisted syntheses included tests 
for best biocatalyst, optimal concentration of aglycone and protein, and incubation time (I, 
II).  An interesting  detail  was  observed  when optimizing  the  incubation  time of  enzyme-
assisted syntheses (II), namely that recombinant human UGTs were active for a much 
longer time than liver microsomes. This would be nice to study more systematically to 
find a possible explanation. Other researchers have found that glucuronidation activity can 
also be affected by the presence of  alamethicin [19, 94-96] and bovine serum albumin 
[97, 98], the concentrations of detergents [94, 96, 97], UDPGlcA [40, 97, 99], and buffer, 
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as well as pH [94, 100]. In the chemical synthesis of clenbuterol glucuronides (IV), 
optimized reaction conditions, or even a chemical method other than the Koenigs-Knorr 
reaction could have been used to increase the yields. Thorough optimization of reaction 
conditions for enzymatic and chemical glucuronide syntheses, however, would increase 
the time and money consumed. As shown in this study, optimization of the most important 
factors is sufficient for easy and efficient synthesis of glucuronide metabolites in 
milligram scale. 
 
It was remarkable that neither hydrolysis nor acyl migration were detected in the 
syntheses of candesartan and zolarsartan O-glucuronides (II), even though acyl 
glucurondies are usually considered to be relatively labile [24, 25]. Acyl glucuronides 
require special attention in drug research because of their possible toxicity [21, 24-27]. 
Studying the instability of acyl glucuronide metabolites of drug candidates is also 
important because such glucuronides are susceptible to enterohepatic circulation, or they 
may otherwise have prolonged action. 
 
Both enzyme-assisted and traditional chemical syntheses of glucuronide metabolites 
had their advantages and disadvantages in this study. Enzyme-catalyzed reactions of 
losartan N2-glucuronide by moose liver microsomes, candesartan O-glucuronide by 
human UGT1A8, and candesartan N2-glucuronide and zolarsartan N2-glucuronide by 
human UGT1A3 were regiospecific (III). In these cases, optimized SPE for the isolation 
of the synthesis products could have been a reasonable alternative to HPLC fractionation 
(II). After incubation, careful removal of proteins from the reaction mixtures and the 
subsequent SPEs were time consuming, but they were important for successful HPLC 
fractionation. Preliminary experiments in small scale needed to be performed before each 
large scale enzyme-assisted synthesis, because the yields were strongly dependent on the 
specific activity of the enzyme preparation that was used as catalyst. In this study the 
Koenigs-Knorr reaction produced sufficient amounts of glucuronides without any 
optimization of the reaction conditions (IV). The synthesis consisted of two steps and was 
fairly simple and straightforward. On the other hand, the reaction mixture included various 
compounds due to formation of intermediate products, which were the protected 
glucuronides from the first step as well as the partially and fully deprotected glucuronides 
from the second step. In addition, the reaction monitoring was difficult. 
 
Taken together, it can be seen that synthesis of milligram amounts of glucuronides by 
enzyme-assisted methods and the Koenigs-Knorr reaction is relatively easy. Based on the 
research done in this study, to synthesize glucuronide metabolites the enzymatic method is 
more convenient if the affinity of the aglycone substrate for the enzyme is high, but 
otherwise the traditional chemical method would generally be preferred. 
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Structural Characterizations 
The MS spectra of the synthesis products in positive and negative ion modes showed 
protonated and deprotonated glucuronides, respectively (I, II, IV). The compounds were 
identified as glucuronides on the basis of m/z values, which were 176 Da higher than those 
of the corresponding aglycones. These glucuronide ions were selected as precursors for 
the MS/MS analysis. In most cases the MS/MS spectra did not show any diagnostic ions 
for the determination of the glucuronidation site. The only exceptions were obtained in the 
negative ion mode MS/MS spectra of clenbuterol glucuronides, which showed abundant 
product ion at m/z 193, corresponding to deprotonated glucuronic acid (IV). This gave 
strong evidence that both clenbuterol glucuronides were O-glucuronides [33, 37, 49]. 
 
Detailed structures of the synthesized glucuronides (Fig. 7) were derived from their 
NMR spectra (I, II, IV). Interglycosidic correlations for determination of the 
glucuronidation sites were observed from NOE, ROESY, and/or HMBC spectra. The 
HMBC spectrum of clenbuterol O-glucuronide 1 is shown as an example in Figure 8 (IV). 
Racemic dobutamine (I) and clenbuterol (IV) aglycones were used as the starting material 
for their glucuronide syntheses. Both syntheses yielded glucuronide diastereomers. HPLC 
with a C18 reversed phase column was used in the isolation of the glucurondies, but it did 
not separate dobutamine diastereomers whereas clenbuterol diastereomers were separated 
easily. It would have been interesting to identify the two clenbuterol O-glucuronide 
diastereomers, but that would have required pure enantiomers of clenbuterol aglycone. 
 
Figure 7 Glucuronidation sites of the synthesized glucuronides. 
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Figure 8 HMBC spectrum of clenbuterol O-glucuronide 1 (I). The arrows indicate the 
correlation between the glucuronic carbon GC1 (102 ppm) and the benzylic proton 
CHO–glucuronide (5.01 ppm) that confirmed the compound as O-glucuronide of 
clenbuterol. 
4.2 Enzyme Activity Assays 
The glucuronidation of dobutamine, losartan, candesartan, zolarsartan, and clenbuterol 
was studied with liver microsomes from various species and with human recombinant 
UGTs (I, III, IV). 
Liver Microsomes 
The analyses of the glucuronidation activity of liver microsomes from various animals 
revealed that there are major differences in glucuronidation properties between species 
(Table 8). Compared to animal liver microsomes, human liver microsomes were typically 
inefficient at glucuronidating the studied aglycones. It would have been useful to find that 
some of the studied animal liver microsomes were good models for predicting drug 
glucuronidation in humans in general, qualitatively or semi-quantitatively. However, that 
kind of trend was not observed in this study. Of the species studied here, rat is probably 
the most common laboratory animal. The glucuronidation profile of rat and human, 
however, were quite different. The interspecies differences in glucuronidation need to be 
carefully taken into account when designing metabolism experiments with drugs that are 
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intended for humans. UGTs in the livers of different animals do not have identical 
function, activity, substrate specificity, or distribution. 
Table 8. Relative formation of different glucuronides from dobutamine (1 mM) (I), losartan 
(1mM) (III), candesartan (1 mM) (III), zolarsartan (1 mM) (III), and clenbuterol 
(1.5 mM) (IV) by liver microsomes from various species.a 
Glucuronide Human Rabbit Rat Pig Moose Bovine Dog 
Dobutamine        
Phenolic O-glucuronide + ++ +++ +++ – – – 
Catecholic para O-
glucuronide 
+ +++* +++ ++ – – – 
Catecholic meta O-
glucuronide 
++ ++ ++ +++ – – – 
        
Losartan        
O-Glucuronide + ++ + + + + – 
N1-Glucuronide + + + + n.d. n.d. – 
N2-Glucuronide ++ ++ ++ ++ +++* ++ – 
        
Candesartan        
Acyl O-glucuronide + ++ +++* + ++ + – 
N2-Glucuronide + + ++ + + + – 
        
Zolarsartan        
Acyl O-glucuronide ++ +++ ++ +++* ++ +++ – 
N1-Glucuronide n.d. n.d. +++ ++ + + – 
N2-Glucuronide + n.d. n.d. + n.d. n.d. – 
        
Clenbuterol        
O-Glucuronide 1 + + ++ + + +++* n.d. 
O-Glucuronide 2 n.d. ++ + n.d. + + +++ 
a+++* = Largest peak area of glucuronide isomer in HPLC chromatograms obtained from microsome 
screening assays using one aglycone; + = < 10%, ++ = 10–50%, +++ = > 50%, a percentage of the largest 
peak area (+++*) of glucuronide isomer; n.d. = not detected; – = not studied. 
Recombinant Human UGTs 
The fact that UGTs have overlapping substrate specificities was shown again in this study. 
Glucuronidation of dobutamine, losartan, candesartan, and zolarsartan was catalyzed by 
several human UGT isoforms (Fig. 9) (I, III). Clenbuterol was glucuronidated only by 
UGTs 1A7, 1A9, and 1A10 (IV). Human UGTs 1A7–1A10 exhibit 83% identity at the 
amino acid sequence level [3], and for UGTs 1A7–1A9 this was reflected in their similar 
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ability to form glucuronide isomers of the studied aglycones. The versatility of UGT1A10 
was an exception in this group (Fig. 9). It was able to efficiently glucuronidate both 
catecholic hydroxyls of dobutamine, not only the hydroxyl in the meta position (I). It was 
also the only isoform that catalyzed the formation of N1- and N2-glucuronide of losartan 
at significant rates (III). UGT1A10 also glucuronidated zolarsartan quite differently than 
UGTs 1A7–1A9; it effectively produced O-glucuronide and to a lesser degree N1-
glucuronide of zolarsartan, whereas UGTs 1A7–1A9 produced only traces, if any, of 
zolarsartan glucuronides (III). 
 
The high regioselectivity of human UGT1A3 towards the tetrazole N2 of sartans was 
remarkable (Fig. 9) (III). UGT1A4 has been considered to be the main N-glucuronidation 
isoform, followed by UGT1A3 [6, 16, 17, 101, 102]. The results of the present study 
revealed that many UGTs are able to catalyze the formation of tetrazole-N-glucuronides, 
although UGT1A4 exhibited no significant activity towards any of the three sartans 
studied here. A probable reason for this is the nature of the tetrazole ring. Tetrazole is 
acidic,  with  a  pKa value of 4.9, whereas amines, which are the more common N-
glucuronidation substrates of UGT1A4, are basic. In addition to tetrazoles, carboxylic 
acids are often glucuronidated by UGT1A3 [11, 21, 24, 101, 103, 104], which can be 
explained by the fact that tetrazoles have been used as non-classical isosteres for 
carboxylic acid moieties in bioactive molecules [105, 106]. It has been previously 
published that UGT1A3 catalyzes N2-glucuronidation of tetrazoles [104, 107], and so the 
results obtained in this study with different tetrazoles strengthens this observation. Based 
on these results, it is likely that other tetrazole-containing compounds, for example 
irbesartan [108, 109], are actively glucuronidated to tetrazole-N2-glucuronides by this 
enzyme.  
 
Zolarsartan could be used as a specific probe for the presence of active UGT1A3 in 
human tissue samples,  since UGT1A3 was the only isoform that catalyzed the formation 
of zolarsartan N2-glucuronide (Fig. 9) (III). However, the glucuronidation is only a minor 
metabolic route for zolarsartan and the amounts of zolarsartan glucuronides were very 
small in the incubation reactions. In practice this would result in insuperable difficulties. 
For example, determining the kinetic parameters for zolarsartan would be very 
challenging; at the least very sensitive analytical equipment and methods would be 
needed. In any case, the results of this study could be exploited in developing a derivative 
with a biphenyl tetrazole-ring structure that could act as a human UGT1A3-selective probe 
compound with high affinity. 
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Figure 9 Glucuronidation activities of recombinant human UGTs towards dobutamine (I), 
losartan (III), candesartan (III), and zolarsartan (III). The normalized activity 
(activity corrected for expression level of individual UGTs) is presented and relative 
expression levels of the different recombinant UGTs are given in parenthesis under 
the enzyme name. Activity results are averages of duplicate samples, where the 
aglycone and protein concentrations were 1 mM and 2.5 mg/ml, respectively, and the 
incubation time was four hours. 
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Predicting glucuronidation in human liver microsomes based on the data obtained with 
recombinant hepatic UGTs was difficult in this study. Although the profile of the 
glucuronide isomer formation of dobutamine, losartan, candesartan, and clenbuterol 
seemed to correlate between the hepatic UGTs and human liver microsomes, the 
glucuronidation of zolarsartan was a bit more complicated (I, III). Despite the high 
zolarsartan glucuronidation activity of UGT1A3, it only has minor involvement in human 
liver microsomes where N2-glucuronide was a minor product (Table 8) (III). This 
situation was also seen in losartan tetrazole-N2-glucuronidation when the kinetics was 
examined using human liver microsomes and UGTs 1A1, 1A3, and 2B7 (Fig. 10) (III). 
UGT1A3 exhibited clear substrate inhibition kinetics, a phenomenon not seen in human 
liver microsomes. The kinetic analyses of UGTs 1A1 and 2B7 suggest that both of them 
contribute significantly, and rather similarly, to losartan glucuronidation by human liver 
microsomes. The explanation for both these observations may be that although UGT1A3 
is expressed in the human liver, its expression level is much lower that that of UGTs 1A1 
and 2B7 [110]. 
 
Figure 10 Kinetics of losartan glucuronidation by human liver microsomes, and recombinant 
human UGTs 1A1, 1A3, and 2B7. The data points were fitted to the Michaelis-Menten 
(human liver microsomes and UGTs 1A1 and 2B7) or the substrate inhibition 
(UGT1A3) equations (III). 
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4 Conclusions 
Drug metabolites are needed for pharmaceutical investigations to study the properties of 
these compounds, as well as the characteristics of the catalyzing enzymes. In this study, 
glucuronide regio- and stereoisomers were synthesized in milligram scale using both 
enzymatic and traditional chemical synthesis methods. Two of the studied aglycones, 
candesartan and zolarsartan, were carboxylic acids that were glucuronidated to acyl 
glucuronides. The possibility that acyl glucuronide metabolites can be toxic must be taken 
into account in drug development. In the enzyme-assisted syntheses of O-glucuronides of 
candesartan and zolarsartan neither hydrolysis nor acyl migration were detected, although 
acyl glucuronides are usually considered to be relatively labile. MS and NMR were used 
for identification and structural characterization of the synthesized glucuronides. Different 
NMR techniques, such as NOE, ROESY, and HMBC, were essential for unambiguous 
determination of the glucuronidation sites of the isomers.  
 
The glucuronidation screening assays with liver microsomes from different species 
revealed that the results obtained with animal models do not necessarily tell much about 
the glucuronidation of the drug in humans. Since no crystallographic structure of any UGT 
is available, the functions and catalytic mechanisms of these enzymes have to be 
investigated by indirect methods. In this study, new knowledge about substrate 
specificities of the UGTs was gained from the screening assays, particularly among 
glucuronide regioisomers. The results of this study have be exploited to study the 
differences between UGTs 1A9 and 1A10, two human UGTs that are very similar at  the 
level of amino acid sequence, but differ greatly in substrate specificity. 
 
In drug discovery, in vitro metabolism studies of a drug candidate are part of the non-
clinical development. However, the compounds studied in this work, except zolarsartan, 
are already in clinical use. Would the drug discovery process of these drugs have been 
changed, if the results obtained in this study were already available at that time? Probably 
not, since all the studied drugs were glucuronidated by several UGTs, reducing the risk of 
drug-drug interactions and adverse reactions caused by polymorphic UGTs.  
Therapeutically notable is the formation of candesartan acyl glucuronide, because the 
metabolite can be toxic. Therefore the binding of candesartan acyl glucuronides to the 
macromolecules and the formation of candesartan acyl glucuronides in vivo would be 
worth further research. 
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